BioLineRx (BLRX) EBIT Margin (2023 - 2025)
Historic EBIT Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 516.86%.
- BioLineRx's EBIT Margin fell 4078800.0% to 516.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.94%, marking a year-over-year increase of 715200.0%. This contributed to the annual value of 70.52% for FY2024, which is 9647700.0% up from last year.
- Per BioLineRx's latest filing, its EBIT Margin stood at 516.86% for Q3 2025, which was down 4078800.0% from 757.57% recorded in Q2 2025.
- BioLineRx's EBIT Margin's 5-year high stood at 37.67% during Q4 2024, with a 5-year trough of 1476.34% in Q3 2023.
- Its 3-year average for EBIT Margin is 539.57%, with a median of 472.37% in 2025.
- In the last 5 years, BioLineRx's EBIT Margin surged by 13673600bps in 2024 and then plummeted by -8673000bps in 2025.
- Over the past 3 years, BioLineRx's EBIT Margin (Quarter) stood at 427.89% in 2023, then soared by 91bps to 37.67% in 2024, then crashed by -1272bps to 516.86% in 2025.
- Its last three reported values are 516.86% in Q3 2025, 757.57% for Q2 2025, and 937.65% during Q1 2025.